Grayscale's ETHE ETF, which offers early access to Ether, charges a 2.5% fee, costing $2,500 annually on a $100,000 investment. BlackRock's newer iShares Ethereum Trust ETF (ETHA) charges only 0.25%, or $250 annually, making it $2,250 cheaper per year for the same Ether exposure. ETHE includes staking rewards, partially offsetting fees but taxable and variable. Investors should consider tax implications and staking income before switching, especially in taxable accounts, while new investors and retirement accounts benefit from ETHA's lower fees without tax costs.
The story on BlackRock's lower Ether holding fees is presented with Pluang market data as of Oct 28, 2026 23:11 WIB. For readers following US stocks on Pluang, 73 of 150 priced stocks rose and 76 fell today. Notable movers include SPCE at USD 2.58 with a 3.90% decrease and balanced 50% sell/buy order activity, HOOD at USD 90.99 down 3.78% with 95% buy orders, and CGC at USD 0.66 down 3.55%.
On National First Responders Day, ADT celebrated local first responders and its monitoring professionals by unveiling a renovated monitoring center in Irving, Texas, part of a $2 million investment. The upgraded center features enhanced equipment and...
Presidio was named Enterprise Partner of the Year and Software and Services Partner of the Year for the Americas at the Cisco Partner Summit 2026. These awards recognize partners who excel in service and innovation, helping customers succeed through ...
Cobalt Boats unveiled the 2027 265 Coastal Edition, a fully redesigned luxury outboard runabout tailored for coastal boating enthusiasts. Featuring wood-free construction, enhanced comfort, and advanced technology like dual 9-inch displays and option...
Air Canada and CAE announced the opening of applications on November 1, 2026, for the 2027 Commandante-Judy-Cameron scholarships. These scholarships support up to eight Canadian women pursuing professional pilot or aircraft maintenance technician tra...
Arcutis Biotherapeutics has appointed Dr. Rob Scott, a seasoned pharmaceutical executive with over 40 years of experience, to its Board of Directors. Dr. Scott's expertise in developing and securing approvals for innovative medicines, including derma...
